<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20231018059760N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2024-01-09</date_registration>
      <primary_sponsor>Mazandaran University of Medical Sciences</primary_sponsor>
      <public_title>The effect of the combined topical gel containing diltiazem, papaverine and lidocaine on hand function, pain, radial artery spasm and sympathetic tone in patients undergoing Trans radial cardiac catheterization</public_title>
      <acronym></acronym>
      <scientific_title>The effect of the combined topical gel containing diltiazem, papaverine and lidocaine on hand function, pain, radial artery spasm and sympathetic tone in patients undergoing Trans radial cardiac catheterization</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2024-01-10</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>48</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/74827</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Triple blinded, Placebo: Used, Assignment: Parallel, Purpose: Prevention, Randomization description: Patients will be placed in one of the two test groups (receiver of combined topical gel of diltiazem, papaverine and lidocaine) and control (placebo) by block randomization method. According to the 6 possible ways of placing letters in blocks of four, these blocks are numbered with numbers one to six.
. (AABB1-ABBA2-BABA3-BBAA4-BABA5-ABAB6) Then, using Random Allocation Software 2.0, one of the numbers one to six will be randomly selected for 12 times. Each number will specify four placement modes in a block. Blocks of four will be placed in 12 non-transparent envelopes in numbered order according to the sequence of random selection and these envelopes will be sealed by someone outside the research team who is unaware of the research objectives and the allocation of people to the groups under study. . The envelopes will be opened in order and the patients will be assigned to the respective groups, Blinding description: It is in the form of three blinds. That is, both the participant and the researchers and the interventionist doctor and the nurse collecting the data will be blind to the placement of the patient in the intervention or placebo group. For this purpose, the drug and placebo will be prepared in same shape and without name labels tubes. These tubes are tagged A and B. Only the principal researcher will know which tube contains drug and which placebo. The patient, nurse and doctor of Cat.Lab. department, data collector and even the statistical analyzer will be unaware of the tubes contents. Patients will be randomly assigned to one of A or B groups in a block method.</study_design>
      <phase>3</phase>
      <hc_freetext>Candidate patients for angiography and angioplasty through the radial artery.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: recipient of combined topical gel. Intervention 2: Control group: receiving placebo gel.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is sss</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Amir Akbari Malekabadi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Taleb Amoli St., Fayaz Bakhsh St</address>
        <city>Amol</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>4771196571</zip>
        <telephone>+98 911 437 4611</telephone>
        <email>Amirakbari0623@gmail.com</email>
        <affiliation>Mazandaran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Roghieh Nazari</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Taleb Amoli St., Fayaz Bakhsh St</address>
        <city>Amol</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>۴۶۱۷۹۳۳۵۸۶</zip>
        <telephone>+98 911 125 6405</telephone>
        <email>rnazari@mazums.ac.ir</email>
        <affiliation>Mazandaran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients with coronary heart disease and clinical candidates for radial catheterization for diagnostic or therapeutic interventions.
Able to understand Persian language
Providing written consent
Age above 18 years
No previous pain and injury in the right hand</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Atrioventricular block
QRS prolongation of more than 120 milliseconds
Parkinson's disease
Long QT intervals of more than 0.44 seconds
breastfeeding
pregnancy
Known liver dysfunction
Type D response in Barbeau test
Acute coronary syndrome
Raynaud's syndrome
Known history of hypersensitivity to local anesthetics
Radial pulse not palpable
Systolic blood pressure drop of less than 90 mmHg
More than two attempts to reach the radial artery
Lack of radial artery access and femoral access as an alternative solution
History of radial artery access in the last 6 months</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: recipient of combined topical gel</i_keyword>
      <i_keyword>Control group: receiving placebo gel</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Radial artery spasm. Timepoint: During catheterization. Method of measurement: Using the radial artery spasm scoring scale.</prim_outcome>
      <prim_outcome>Hand function. Timepoint: before the start of catheterization and two hours after catheter removal. Method of measurement: Using the tool: HAKIR Questionnaire (HQ-8).</prim_outcome>
      <prim_outcome>The pain. Timepoint: Before, during and after catheterization. Method of measurement: using visual analog scale (VAS).</prim_outcome>
      <prim_outcome>Sympathetic tone. Timepoint: Before, during and after catheterization. Method of measurement: Using a hemodynamic monitoring device and a pulse oximeter.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Number of attempts to access the radial artery. Timepoint: During catheterization. Method of measurement: It will be calculated as the number of passes of the needle through the skin and will be observed and recorded by the researcher.</sec_outcome>
      <sec_outcome>Lack of access to the radial artery. Timepoint: During catheterization. Method of measurement: The sheath cannot be inserted or pressure is not detected.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Mazandaran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-12-09</approval_date>
        <contact_name>Research Ethics Committees of Mazandaran University of Medical Sciences</contact_name>
        <contact_address>Moallem Sq Sari Mazandaran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
